Nephrology ·
FDA flags overheating cords on Tablo hemodialysis system; dropping race reshapes dialysis mortality rankings; FIELD tests GFR slope

Listen to this post
read by AI voices · all episodesTHE SHORT READ
The Food and Drug Administration (FDA) issued an early alert Nov. 18 on overheating power cord connections on Outset Medical's Tablo hemodialysis system. A study of 6,895 dialysis facilities found that removing race and ethnicity from mortality risk adjustment altered publicly reported performance, and a FIELD trial reanalysis tested GFR slope as an end point when a drug causes an acute eGFR change.
THE DETAILS
- FDA Nov 18, 2026The Food and Drug Administration (FDA) issued an early alert Nov. 18 on Outset Medical's Tablo Console and TabloCart with Prefiltration Drawer after reports of overheating at the connection between the power cord and the power inlet. A person touching an overheated connector could receive a first- or second-degree burn, and the console may lose power, which could delay, interrupt or cause a missed treatment, according to the FDA. Outset told customers not to use extension cords or power strips, and as of Nov. 10 it had reported no serious injuries or deaths.Source: FDA
- Research Nov 16, 2026A cross-sectional study of 6,895 dialysis facilities, published online Nov. 16 in JAMA Internal Medicine, recalculated the standardized mortality ratio used in dialysis quality measurement without race and ethnicity. After removal, the difference in the ratio between facilities with high and low social risk was nearly eliminated, to -0.002, and 1,259 high-social-risk facilities (21.6%) improved in ranking. The authors said removing race and ethnicity substantially altered publicly reported mortality performance.Sources: JAMA Internal Medicine, PubMed
- Research Nov 19, 2026A secondary analysis of the FIELD trial of fenofibrate versus placebo, published online Nov. 19 in Kidney International, tested GFR slope as a trial end point when a drug causes an acute eGFR change. Fenofibrate produced an acute eGFR decline of 9.05 mL/min/1.73 m2, improved chronic slope (between-group difference 0.61) and worsened total slope (difference -1.54), and it increased the clinical end point (hazard ratio 1.48, 95% CI 1.16 to 1.89). The authors said total slope and the conventional composite gave concordant treatment effects.Sources: Kidney International, PubMed
The weekly innovation roundup for nephrology, published every Sunday for the week before; every item links to its sources. Latest nephrology news · All specialties